Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 07 2025
0mins
Source: Newsfilter
Virpax Pharmaceuticals' Vaccine Development: Virpax Pharmaceuticals is exploring the use of its Molecular Envelope Technology (MET) to deliver an mRNA COVID vaccine intranasally, aiming for a safer alternative to current lipid-based delivery methods.
Product Candidates and Partnerships: The company is developing non-addictive pain management products, including Envelta™ for acute pain and NobrXiol™ for pediatric epilepsy, while seeking FDA approval and partnerships for additional drug candidates targeting viral infections and osteoarthritis pain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
